News

The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.

PharmaEssentia Receives Taiwan Approval for BESREMi in Essential Thrombocythaemia

Thursday, June 11, 2026

PharmaEssentia has received approval from Taiwans Ministry of Health and Welfare MOHW for BESREMi ropeginterferon alfabnjft to treat adult patients with essential thrombocythaemia ET

IMAAVY Shows Durable Haemoglobin Response in Phase 2/3 Study for Warm Autoimmune Haemolytic Anaemia

Thursday, June 11, 2026

Johnson Johnson has reported positive results from the Phase ENERGY study showing that IMAAVY nipocalimabaahu achieved a statistically significant and durable haemoglobin response in patients with warm

FloBiotech Signs Agreement with UCLA Health to Advance Neurodegenerative Disease Treatments

Wednesday, June 10, 2026

FloBiotech has entered into an agreement with UCLA Health to support the development of a new class of therapies for neurodegenerative diseases by targeting protective biological pathways involved in disease progression

Engitix and GSK Partner to Advance New Targets for Liver Fibrosis Treatment

Tuesday, June 09, 2026

Engitix has entered into a strategic research collaboration and option agreement with GSK to identify and validate novel therapeutic targets aimed at promoting liver fibrosis regression

FDA Expands Approval of Pfizer’s HYMPAVZI for Additional Hemophilia A and B Patient Groups

Tuesday, June 09, 2026

Pfizer has received approval from the US Food and Drug Administration FDA for an expanded indication of HYMPAVZI marstacimabhncq extending its use to patients aged years and older with hemophilia

Teva launches AHZANTIVE biosimilar to Eylea across Europe

Friday, June 05, 2026

Teva Pharmaceutical Industries has launched AHZANTIVE aflibercept a biosimilar to Eylea in Europe expanding its biosimilars portfolio and strengthening its presence in the ophthalmology sector

Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

Friday, June 05, 2026

Biogen has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy Designation to salanersen for the treatment of spinal muscular atrophy SMA

Lundbeck Partners with Cradle to Advance AI-Driven Brain Disorder Treatments

Thursday, June 04, 2026

H Lundbeck AS has entered a partnership with Cradle to support the discovery and optimisation of biotherapeutics for brain disorders using artificial intelligence

Lupin and Natco Receive US FDA Approval for Eribulin Mesylate Injection

Wednesday, June 03, 2026

Lupin Limited and its alliance partner Natco Pharma have received approval from the US Food and Drug Administration FDA for Natcos Abbreviated New Drug Application ANDA for Eribulin Mesylate Injection mg mL

Haisco and Lilly Enter Research and Licensing Partnership for Innovative Medicines

Tuesday, June 02, 2026

Haisco Pharmaceutical Group Co Ltd has entered into a licensing and research collaboration with Eli Lilly and Company to develop innovative medicines across multiple therapeutic areas